Pathstone Family Office’s Takeda Pharmaceutical TAK Stock Holding History

Pathstone Family Office’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$203K	Buy	+13,094	New	+$203K	﹤0.01%	1515
2023 Q1	–	Sell	-44,422	Closed	-$462K	–	1481
2022 Q4	$462K	Buy	44,422 +20,925	+89%	+$292K	﹤0.01%	1135
2022 Q3	$305K	Buy	+23,497	New	+$327K	﹤0.01%	1221

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Pathstone Family Office's TAK Position: Q3 2023 in Review

Pathstone Family Office opened a new position in Takeda Pharmaceutical (TAK) in Q3 2023: 13,094 shares worth $203K. The stake represents ﹤0.01% of the portfolio and ranks #1515 among its holdings. This is a return to the name: Pathstone Family Office previously reported a position in TAK as recently as Q4 2022.

Pathstone Family Office first reported a position in TAK in Q3 2022 and has held it in 3 quarters since. The position peaked at $462K in Q4 2022. 312 funds tracked by Wall St. Rank hold TAK as of Q3 2023.

Pathstone Family Office held 13,094 shares of Takeda Pharmaceutical worth $203K as of Q3 2023.
Takeda Pharmaceutical was a new Pathstone Family Office position in Q3 2023.
Takeda Pharmaceutical made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1515 holding.
Pathstone Family Office first reported a position in Takeda Pharmaceutical in Q3 2022 and has held it in 3 quarters since.
Pathstone Family Office's Takeda Pharmaceutical position peaked at $462K in Q4 2022.
312 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.